SEEKYO® is a privately-owned biotech company developing a Smart Chemotherapy, selective to tumors, safe for patients.
We are designing smart drugs that selectively target the microenvironment of solid tumors while sparing healthy tissues.
We help increasing cancer patient’s quality of life by providing efficient and selective treatments without adverse effects.
Chemotherapy is one of the main therapeutic option for cancer patients.
However, most anticancer drugs used clinically (standard chemotherapy) lack any intrinsic selectivity, causing severe side effects as the result of their toxicity toward healthy tissues.
Selectivity is key to ensure the drugs only act on cancer cells, sparing all other tissues. At SEEKYO® we have developed a completely new approach, a double targeting of the Tumor Micro-Environment
We call it Smart chemotherapy
With the aim of offering improved treatments to cancer patients, SEEKYO‘s therapeutic vectors are
SEEKYO®’s unique technology comprises a molecular platform enabling the custom design of almost any type of therapeutic vector.
This versatile linker technology offers the possibility to design “on demand” the most appropriate targeting assembly in order to treat a given malignancy, based on its unique tumor-associated specificities.
SEEKYO®’s self-immolative linker can gather in a single molecular entity:
Step 1. SKY 01 binds covalently to circulating albumin leading to the formation of the bioconjugate
Step 2. The bioconjugate accumulates in the tumor microenvironment where enzymatic activation triggers the release of the drug molecules.
Step 3. The drugs penetrate inside surrounding cancer cells to exert their anticancer activity.
The versatility of the technology allows:
The development of the next generation of
smart therapeutic vectors targeting the
In optimizing the efficacy of current
Antibody Drug Conjugates (ADC)